Biocon Biologics Secures Europe Market Entry for Denosumab Biosimilars

**Bengaluru, December 2, 2025:** Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has secured the **commercial market entry date** for its Denosumab biosimilars **Vevzuo®** and **Evfraxy®** across Europe and key international markets after reaching a settlement agreement with Amgen Inc. Commercialization will begin from **December 2, 2025**, unlocking new opportunities in the oncology and bone-health segments. The European Commission had approved both biosimilars in July 2025, enabling Biocon to address rising global demand for cost-effective treatments for osteoporosis, bone metastases, and giant cell tumour of bone. The achievement follows the company’s earlier U.S. market entry settlement for its Denosumab products Bosaya™ and Aukelso™. With 10 commercialized biosimilars and a robust pipeline of 20 assets, Biocon Biologics continues to strengthen its global footprint in affordable biologics. **Disclaimer:** This article is for informational and news purposes only and should not be considered investment advice. **Follow for more:** Stay updated with the latest market news, corporate actions, and financial insights.